Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its ATLAS platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Co.'s GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral cells (NPTs). The GEN-011 NPTs are specific for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived, tumor-specific T cell therapy. Co.'s GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The GNCA stock yearly return is shown above.
The yearly return on the GNCA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GNCA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|